TABLE 1.
Baseline characteristics and antibody response.
| Variable | HD | Control | p-value |
| No. | 104 | 84 | |
| Age (years), mean ± SD | 73.1 ± 11.6 | 64 ± 10.9 | <0.001 |
| Female gender (%) | 33 (31.7%) | 45 (53.6%) | 0.003 |
| DM (%) | 62 (59.6%) | 11 (13%) | <0.001 |
| BMI (kg/m2), mean ± SD | 26.8 ± 5.2 | 26.6 ± 3.5 | 0.827 |
| Time since second vaccine dose to 6-month serology median (IQR) | 184 (183–188) | 203 (196–207) | <0.001 |
| Ab level 6-month (AU/ml) Median (IQR) | 147.1 (61.8–433.6) | 588.8 (317.6–939.1) | <0.001 |
| Log Ab level 6-month (log AU/ml) mean ± SD | 2.23 ± 0.39 | 2.69 ± 0.65 | <0.001 |
| Adjusted log Ab level (EMM) (95% CI) | 2.3 (2.19–2.41) | 2.63 (2.49–2.77) | 0.001 |
| Seronegative (%) | 21 (20.2%) | 1 (1.2%) | <0.001 |
DM, diabetes mellitus; BMI, body mass index; EMM, estimated marginal mean; IQR, interquartile range; CI, confidence interval; SD, standard deviation.